Across the Spectrum: Transforming the Detection and Management of Disease State Transitions Across the Spectrum of Multiple Sclerosis
Multiple sclerosis (MS) is a disease of transitions from subclinical changes to isolated events to definite MS. These clinical developments are often accompanied by changes in disease states ranging from active to inactive. But with increasing recognition that progressive pathologies may begin early in MS, the lines between disease states are beginning to blur.
Given the variable implications of such changes, it is important to recognize when and how these transitions require alterations in management strategies. To help MS clinicians evaluate risk for, identify, and respond to several key types of transitions in MS, this program utilizes four instructional cases that illustrate transitions across the MS spectrum. Through modern literature and their own strategies, faculty will walk through optimal approaches to corresponding clinical decisions.
This activity is intended for general neurologists, neurodegenerative disease specialists, nurse practitioners, physician assistants, and other healthcare professionals involved in the diagnosis and long-term management of patients with MS.
Upon completion of the educational activity, participants should be able to:
- Discuss the available strategies for evaluating different MS transitions to employ appropriate and practical approaches for identifying patient changes over the course of their disease
- Appraise available evidence and clinical experience with different disease-modifying therapy (DMT) strategies in preclinical and relapsing MS to help delineate optimal treatment pathways for individuals at varying risk of advancing to clinically definite MS (CDMS) or secondary progressive MS (SPMS)
- Evaluate the varying factors that may influence disease trajectory and treatment response in patients with inactive disease to determine when and for whom DMT switching or discontinuation may be appropriate
Erin Longbrake, MD, PhD (Moderator & Chair)
Assistant Professor of Neurology
Program Director, Neuroimmunology Fellowship
Director, Clinical Research in Neuroimmunology
New Haven, CT
Robert Bermel, MD
Director and Staff Neurologist,
Mellen Center for Multiple Sclerosis
Jacqueline A. Nicholas, MD, MPH
System Chief, Neuroimmunology & MS
OhioHealth MS Center
This activity is jointly provided by Medical Education Resources and Efficient LLC.
In support of improving patient care, this activity has been planned and implemented by Medical Education Resources (MER) and Efficient LLC. MER is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Disclosure of Relevant Financial Relationships
Efficient LLC and Medical Education Resources' planners and managers have no financial relationships to disclose.
Erin Longbrake, MD, PhD:
- Consulting Fees: Biogen, Bristol Myers Squibb, EMD Serono, Genentech, Genzyme, Janssen, NGM Bio, TG Therapeutics
- Grants/Research Support: Biogen, Genentech
Robert Bermel, MD:
- Consulting fees: AstraZeneca, Biogen, EMD Serono, Sanofi, Genentech, LabCorp, Lilly, Novartis, TG Therapeutics, Horizon
- Grants/Research Support: Biogen, Genentech, Novartis
Jacqueline A Nicholas, MD:
- Consulting Fees: EMD Serono, Genentech, Novartis, Sanofi, TG Therapeutics
- Grants/Research Support: Biogen, Genentech, Novartis, University of Buffalo
- Speakers' Bureau: EMD Serono, TG Therapeutics
Disclosure of Unlabeled Use/Disclaimer
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Medical Education Resources, Efficient LLC, and/or Genentech. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.
This continuing education activity is supported by an educational grant from Genentech, a member of the Roche Group.
Method of Participation
There are no fees for participating in and receiving credit for this activity. During the period November 15, 2023 through November 15, 2024, participants must 1) read the learning objectives and faculty disclosures; 2) complete the pre-assessment; 3) study the educational activity; 4) complete the post-test by recording the best answer to each question; and 5) complete the evaluation form.
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Attendance